impact factor, citescore
logo
 

Full Papers

 

Adherence to medication during pregnancy in systemic autoimmune diseases: results from a prospective study


1, 2, 3, 4, 5, 6, 7

 

  1. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, and Department of Medical Biotechnologies, University of Siena, Italy.
  2. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  3. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  5. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  6. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiara.tani@for.unipi.it
  7. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

CER16981
2024 Vol.42, N°3
PI 0666, PF 0670
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 37812486 [PubMed]

Received: 07/07/2023
Accepted : 18/09/2023
In Press: 05/10/2023
Published: 27/03/2024

Abstract

OBJECTIVES:
To evaluate adherence to medication in patients with systemic autoimmune diseases (SAD), comparing pregnant and non-pregnant women.
METHODS:
200 patients with SAD were consecutively enrolled, 100 pregnant and 100 non-pregnant women. Each patient completed the 8-item Morisky Medication Adherence Scale (MMAS-8), one copy for hydroxychloroquine (HCQ) and one for other treatments for rheumatic disease, and Hospital Anxiety and Depression Scale (HADS).
RESULTS:
No significant differences were found in ongoing therapies between pregnant and non-pregnant women. 148 patients (74.0%) were taking HCQ and 160 (80.0%) other therapies for rheumatic disease. The mean MMAS-8 score was >6 in all groups indicating a good adherence, on average. The rate of patients with good medication adherence was higher in pregnant patients (73.9% vs. 63.3% and 76.5% vs. 64.5%, for HCQ and other therapies, respectively) although this difference was not statistically significant. Eight patients had very poor medical adherence, and all were non-pregnant women. Anxiety (15% of patients) was associated to low medication adherence for drugs other than HCQ (p=0.02), while depression (4% of patients) did not seem to have an impact on adherence.
CONCLUSIONS:
In our cohort we recorded a good adherence to prescribed medication, although adequate adherence was not achieved in about 30% of patients, confirming that non-adherence is an important issue in SAD. It is difficult to define a profile of patients at risk of poor adherence, but it appears important to implement communication and adherence monitoring strategies since strict monitoring also during pregnancy could improve medical adherence.

DOI: https://doi.org/10.55563/clinexprheumatol/st5fl0

Rheumatology Article